AR101036A1 - Amidas de benzoxazinona como reguladores del receptor mineralocorticoide - Google Patents

Amidas de benzoxazinona como reguladores del receptor mineralocorticoide

Info

Publication number
AR101036A1
AR101036A1 ARP150102098A ARP150102098A AR101036A1 AR 101036 A1 AR101036 A1 AR 101036A1 AR P150102098 A ARP150102098 A AR P150102098A AR P150102098 A ARP150102098 A AR P150102098A AR 101036 A1 AR101036 A1 AR 101036A1
Authority
AR
Argentina
Prior art keywords
benzoxazinona
amidas
mineralocorticoid
regulators
receiver
Prior art date
Application number
ARP150102098A
Other languages
English (en)
Spanish (es)
Inventor
Carl Hogner Anders
Kajanus Johan
Edman Karl
Kossenjans Michael
Omahony Gavin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR101036A1 publication Critical patent/AR101036A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ARP150102098A 2014-06-30 2015-06-30 Amidas de benzoxazinona como reguladores del receptor mineralocorticoide AR101036A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462018790P 2014-06-30 2014-06-30

Publications (1)

Publication Number Publication Date
AR101036A1 true AR101036A1 (es) 2016-11-16

Family

ID=53539739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102098A AR101036A1 (es) 2014-06-30 2015-06-30 Amidas de benzoxazinona como reguladores del receptor mineralocorticoide

Country Status (26)

Country Link
US (2) US10017502B2 (OSRAM)
EP (1) EP3160948B1 (OSRAM)
JP (1) JP6368383B2 (OSRAM)
KR (1) KR102012222B1 (OSRAM)
CN (1) CN106536491B (OSRAM)
AR (1) AR101036A1 (OSRAM)
AU (1) AU2015282450C1 (OSRAM)
CA (1) CA2953655C (OSRAM)
CY (1) CY1121596T1 (OSRAM)
DK (1) DK3160948T3 (OSRAM)
EA (1) EA029518B1 (OSRAM)
ES (1) ES2707726T3 (OSRAM)
HR (1) HRP20190147T1 (OSRAM)
HU (1) HUE042370T2 (OSRAM)
LT (1) LT3160948T (OSRAM)
ME (1) ME03316B (OSRAM)
MX (1) MX367404B (OSRAM)
PL (1) PL3160948T3 (OSRAM)
PT (1) PT3160948T (OSRAM)
RS (1) RS58274B1 (OSRAM)
SI (1) SI3160948T1 (OSRAM)
SM (1) SMT201900039T1 (OSRAM)
TR (1) TR201900659T4 (OSRAM)
TW (1) TWI677498B (OSRAM)
UY (1) UY36195A (OSRAM)
WO (1) WO2016001631A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2707726T3 (es) * 2014-06-30 2019-04-04 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides
PE20210644A1 (es) 2018-07-19 2021-03-23 Astrazeneca Ab METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
CN112107568B (zh) * 2019-06-19 2022-03-25 北京龙嘉博创医药科技有限公司 二芳基酰胺类化合物及其应用
CR20200224A (es) * 2019-08-30 2021-05-26 Astrazeneca Ab Composiciones y métodos de tratamiento de la insuficiencia cardiaca con fracción de eyección reducida con dapagliflozina
WO2022022865A1 (en) 2020-07-27 2022-02-03 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
MX2023015144A (es) * 2021-06-15 2024-01-22 Chia Tai Tianqing Pharmaceutical Group Co Ltd Derivados de benzoxazinona.
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
CR20250112A (es) 2022-09-01 2025-08-18 Aztrazeneca Ab Combinación de ihnibidores de sglt2 y moduladores del receptor mineralcorticoide para usar en el tratamiento de enfermedades cardiorrenales
WO2024125591A1 (zh) * 2022-12-15 2024-06-20 正大天晴药业集团股份有限公司 苯并恶嗪酮类化合物的结晶及其制备
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528335A (ja) * 2001-04-23 2004-09-16 アストラゼネカ アクチボラグ 血管新生の治療に使用のベンゾオキサジノン誘導体
JP2006512357A (ja) * 2002-12-20 2006-04-13 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Pi3kの阻害剤としてのベンゾキサジンおよびその誘導体
JP2008506689A (ja) * 2004-07-14 2008-03-06 リガンド・ファーマシューティカルズ・インコーポレイテッド 細胞間受容体のモジュレーター化合物および方法
WO2006015259A2 (en) 2004-07-28 2006-02-09 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2007077961A2 (en) 2005-12-28 2007-07-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
GEP20115239B (en) 2006-10-31 2011-06-10 Pfizer Prod Inc Pyrazoline compounds as mineralocorticoid receptor antagonists
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
CA2681134A1 (en) 2007-03-23 2008-10-02 Merck & Co., Inc. Mineralocorticoid receptor modulators
KR101477579B1 (ko) 2007-04-09 2014-12-30 다이이찌 산쿄 가부시키가이샤 피롤 유도체의 아트로프 이성체
JP5173653B2 (ja) * 2007-08-01 2013-04-03 田辺三菱製薬株式会社 医薬組成物
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
UY31905A (es) * 2008-06-18 2010-01-29 Astrazeneca Ab Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2010098286A1 (ja) 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬
BRPI1009257A2 (pt) 2009-03-12 2016-03-08 Lilly Co Eli antagonista receptor de mineralocorticoide e métodos de uso.
EP2417121A1 (en) 2009-04-10 2012-02-15 Pfizer Inc. 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
EP2569576B1 (en) 2010-05-11 2016-07-06 Koninklijke Philips N.V. Lighting module
JP2013528598A (ja) 2010-05-11 2013-07-11 ファイザー・インク ミネラルコルチコイド受容体拮抗薬としてのモルホリン化合物
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
JP2013542255A (ja) 2010-11-10 2013-11-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ミネラルコルチコイド受容体アンタゴニストとしてのピリジル尿素
ES2707726T3 (es) * 2014-06-30 2019-04-04 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides

Also Published As

Publication number Publication date
CA2953655A1 (en) 2016-01-07
AU2015282450C1 (en) 2018-09-20
ES2707726T3 (es) 2019-04-04
KR20170021883A (ko) 2017-02-28
UY36195A (es) 2016-01-08
AU2015282450B2 (en) 2018-05-10
CN106536491A (zh) 2017-03-22
KR102012222B1 (ko) 2019-10-21
SMT201900039T1 (it) 2019-02-28
PL3160948T3 (pl) 2019-04-30
MX2017000183A (es) 2017-04-25
US20170217945A1 (en) 2017-08-03
LT3160948T (lt) 2019-02-11
EP3160948B1 (en) 2018-10-24
WO2016001631A1 (en) 2016-01-07
DK3160948T3 (en) 2019-02-18
US10017502B2 (en) 2018-07-10
TWI677498B (zh) 2019-11-21
EA029518B1 (ru) 2018-04-30
CA2953655C (en) 2020-05-12
JP6368383B2 (ja) 2018-08-01
TR201900659T4 (tr) 2019-02-21
JP2017522300A (ja) 2017-08-10
EA201790046A1 (ru) 2017-08-31
ME03316B (me) 2019-10-20
TW201613909A (en) 2016-04-16
US9394291B2 (en) 2016-07-19
CN106536491B (zh) 2018-12-18
CY1121596T1 (el) 2020-05-29
PT3160948T (pt) 2019-02-01
EP3160948A1 (en) 2017-05-03
SI3160948T1 (sl) 2020-06-30
HRP20190147T1 (hr) 2019-03-22
HUE042370T2 (hu) 2019-06-28
MX367404B (es) 2019-08-20
AU2015282450A1 (en) 2017-02-02
US20150376170A1 (en) 2015-12-31
RS58274B1 (sr) 2019-03-29

Similar Documents

Publication Publication Date Title
AR101036A1 (es) Amidas de benzoxazinona como reguladores del receptor mineralocorticoide
IL287331A (en) Use of 3-isoxazolidinones compounds as selective herbicides
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
BR112017006253A2 (pt) novos compostos
EA201501142A1 (ru) Гетероциклические соединения в качестве средств для борьбы с вредителями
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
CL2016002011A1 (es) Derivados de heterociclos bicíclicos condensados sustituidos con 2-(het)arilo como agentes para combatir parásitos
LT3159409T (lt) Antiprasminė nukleorūgštis, skirta panaudoti diušeno raumenų distrofijos gydymui
EA201791304A1 (ru) Производные изохинолина для лечения вич
CL2016002731A1 (es) Herbicidas de piridazinona
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
DK3497081T3 (da) Fremgangsmåde til fremstilling af 4-ammonium-2,2,6,6-tetraalkylpiperidinylsalte
EA201790983A1 (ru) Синтез копанлисиба и его дигидрохлорида
LT3210973T (lt) Heteroarilo junginiai, skirti akių ligų gydymui
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
BR112016027691A2 (pt) Composto de tetra-hidropiridopirimidina e seus usos
TW201613912A (en) Bicyclic compounds as pesticides
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
MX384794B (es) Proceso para la preparacion de 5-fluoro-1h-pirazoles a partir de hexafluoropropeno.
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы

Legal Events

Date Code Title Description
FG Grant, registration